NeoGenomics, Inc. - Common Stock · Transaction Aug 7, 2026 · Filed Sep 10, 2026 · $1,001 to $15,000
XNAS · NEO
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
NeoGenomics, Inc.
SERVICES-TESTING LABORATORIES
$17.78
Follow $NEO
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $NEO by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredThu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET · NEO
MethodologyNEO
NeoGenomics, Inc.
Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
64/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is NEO moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About NeoGenomics, Inc.
SERVICES-TESTING LABORATORIESListed since
1996
Employees
3K
Country
US
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$17.78
Last session
Day high
$17.78
Last session
Day low
$17.78
Last session
Previous close
$17.78
52W high
$19.91
-10.70% from high
52W low
$7.19
83% of range
Market cap
$2.3B
Beta
0.68
Shares out
128.5M
Avg volume
2M
VWAP
$17.78
Last session
Price history computed in-house
1W
-8.02%
1M
+2.18%
3M
+17.28%
1Y
+98.00%
YTD
+51.19%
SMA 50 $17.12 · above
SMA 200 $12.29 · above
52W position 83%
NEO overview
Related filings and maps
Public disclosures
Congress activity in NEO
Official filing ↗
NeoGenomics, Inc. - Common Stock · Transaction May 7, 2025 · Filed Jun 6, 2025 · $1,001 to $15,000
Dwight EvansSell
NeoGenomics, Inc. · Transaction Mar 30, 2022 · Filed Apr 25, 2022 · $1,001 to $15,000
Neogenomics, Inc. · Transaction Dec 30, 2021 · Filed Jan 8, 2022 · $15,001 to $50,000
Bob GibbsSell
NeoGenomics, Inc. · Transaction Nov 9, 2021 · Filed Nov 14, 2021 · $1,001 to $15,000
Federal contracts
NEO contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NEO in this window.
Lobbying spend
NEO lobbying filings, year to date.
Registered lobbying filings matched to NeoGenomics, Inc..
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NEO in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for NEO.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.